{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:54:10Z","timestamp":1771656850776,"version":"3.50.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> In April 2015, ivabradine was approved by the Food and Drug Administration for the treatment of patients with coronary artery disease and heart failure (HF). The use of this medication has been linked with improved clinical outcomes and reduced rates of hospitalization in patients with symptomatic HF and a baseline heart rate of 70 bpm and above. Nonetheless, little is known about the use of ivabradine in pediatric patients with supraventricular tachycardia (SVT). This use is not well-studied and is only endorsed by a few case reports and case series.<\/jats:p><jats:p><jats:bold>Aim:<\/jats:bold> This study discusses the off-label utilization of ivabradine in pediatric patients with SVT, and highlights its efficacy in treating treatment-resistant (refractory) SVT.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We conducted a retrospective single-center observational study involving pediatric patients with SVT treated at our center between January 2016 and October 2020. We identified the total number of patients with SVT, and the number of patients with refractory SVT treated with Ivabradine. Similarly, we performed a thorough review of the databases of PubMed, Medline and Google Scholar to compare the clinical course of our patients to those described in the literature.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Between January 2016 and October 2020, 79 pediatric patients with SVT were seen and treated at our center. A treatment-resistant SVT was noted only in three patients (4%). Ivabradine was used in these patients as a single or combined therapy. The rest (96%) were successfully treated with conventional anti-arrhythmics such as \u03b2-blockers, flecainide, and other approved medications. In the ivabradine group, successful reversal to sinus rhythm was achieved in two of the three patients (66%), one patient was treated with a combination therapy of amiodarone and ivabradine, and the other patient was treated only with ivabradine.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Overall, promissory results are associated with the use of ivabradine in pediatric patients with refractory SVT. Ivabradine appears to be a safe and well-tolerated medication that can induce adequate suppression of SVT, complete reversal to sinus rhythm, and effective enhancement of left ventricular function.<\/jats:p>","DOI":"10.3389\/fcvm.2021.660855","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T04:28:22Z","timestamp":1627964902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Ivabradine: A Potential Therapeutic for Children With Refractory SVT"],"prefix":"10.3389","volume":"8","author":[{"given":"Nour K.","family":"Younis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Abi-Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Al Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"El Sedawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Tayeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"Bitar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"B1","first-page":"56","article-title":"Corlanor (ivabradine), first HCN channel blocker, FDA approved for the treatment of patients with heart failure","volume":"9","author":"Fala","year":"2016","journal-title":"Am Health Drug Benefits."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"the clinical use of ivabradine","volume":"70","author":"Koruth","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/2042098610393209","article-title":"Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure","volume":"2","author":"Rushworth","year":"2011","journal-title":"Ther Adv Drug Saf."},{"key":"B4","article-title":"Ivabradine","author":"Reed","year":"2020"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","article-title":"Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease","volume":"64","author":"Difrancesco","year":"2004","journal-title":"Drugs."},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003495-200767002-00003","article-title":"The funny current: cellular basis for the control of heart rate","volume":"2","author":"Difrancesco","year":"2007","journal-title":"Drugs 67 Suppl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1152\/physrev.00029.2008","article-title":"Hyperpolarization-activated cation channels: from genes to function","volume":"89","author":"Biel","year":"2009","journal-title":"Physiol Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.2174\/092986711796642427","article-title":"Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutical targets","volume":"18","author":"Koncz","year":"2011","journal-title":"Curr Med Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.3390\/ijms16023071","article-title":"Pacemaker activity of the human sinoatrial node: an update on the effects of mutations in HCN4 on the hyperpolarization-activated current","volume":"16","author":"Verkerk","year":"2015","journal-title":"Int J Mol Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/CIRCRESAHA.109.208041","article-title":"The role of the funny current in pacemaker activity","volume":"106","author":"Difrancesco","year":"2010","journal-title":"Circ Res."},{"key":"B11","first-page":"810","article-title":"Ivabradine (Corlanor) for heart failure: the first selective and specific I f inhibitor","volume":"40","author":"Tse","year":"2015","journal-title":"P T."},{"key":"B12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1253\/circj.CJ-18-1184","article-title":"Ivabradine for the treatment of cardiovascular diseases","volume":"83","author":"Ide","year":"2019","journal-title":"Circ J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.bjp.0706940","article-title":"Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity","volume":"150","author":"Thollon","year":"2007","journal-title":"Br J Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/CIRCULATIONAHA.115.018094","article-title":"Ivabradine: role in the chronic heart failure armamentarium","volume":"133","author":"Psotka","year":"2016","journal-title":"Circulation."},{"key":"B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00002018-200831020-00001","article-title":"I f inhibition with ivabradine: electrophysiological effects and safety","volume":"31","author":"Savelieva","year":"2008","journal-title":"Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jsha.2019.05.006","article-title":"Safety and efficacy of off-label use of ivabradine in patients with acute heart failure","volume":"31","author":"Othman","year":"2019","journal-title":"J Saudi Heart Assoc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e007387","DOI":"10.1161\/CIRCEP.119.007387","article-title":"Clinical and electrophysiological correlates of incessant ivabradine-sensitive atrial tachycardia","volume":"12","author":"Banavalikar","year":"2019","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1540-8167.2010.01860.x","article-title":"Reversal of tachycardiomyopathy due to left atrial tachycardia by ivabradine","volume":"22","author":"Bohora","year":"2011","journal-title":"J Cardiovasc Electrophysiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/jce.12636","article-title":"A case of atrial tachycardia treated with ivabradine as bridge to ablation","volume":"26","author":"Meles","year":"2015","journal-title":"J Cardiovasc Electrophysiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/jce.12081","article-title":"Potential new indication for ivabradine: treatment of a patient with congenital junctional ectopic tachycardia","volume":"24","author":"Al-Ghamdi","year":"2013","journal-title":"J Cardiovasc Electrophysiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.hrthm.2016.03.015","article-title":"Adjunctive ivabradine in combination with amiodarone: a novel therapy for pediatric congenital junctional ectopic tachycardia","volume":"13","author":"Dieks","year":"2016","journal-title":"Heart Rhythm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ihj.2017.09.007","article-title":"Ivabradine for junctional ectopic tachycardia in post congenital heart surgery","volume":"69","author":"Kumar","year":"2017","journal-title":"Indian Heart J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/pace.13402","article-title":"Ivabradine is an effective antiarrhythmic therapy for congenital junctional ectopic tachycardia-induced cardiomyopathy during infancy: case studies","volume":"41","author":"Ergul","year":"2018","journal-title":"Pacing Clin Electrophysiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s00246-011-9964-1","article-title":"A pediatric case of cardiomyopathy induced by inappropriate sinus tachycardia: efficacy of ivabradine","volume":"32","author":"Romeo","year":"2011","journal-title":"Pediatr Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40256-017-0248-x","article-title":"Ivabradine in postural orthostatic tachycardia syndrome: preliminary experience in children","volume":"18","author":"Delle Donne","year":"2018","journal-title":"Am J Cardiovasc Drugs."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jacc.2017.07.725","article-title":"Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure","volume":"70","author":"Bonnet","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00246-019-02149-5","article-title":"Ivabradine in post-operative junctional ectopic tachycardia (JET): breaking new ground","volume":"40","author":"Krishna","year":"2019","journal-title":"Pediatr Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1177\/2150135119876600","article-title":"Ivabradine as an adjunct for refractory junctional ectopic tachycardia following pediatric cardiac surgery: a preliminary study","volume":"10","author":"Kumar","year":"2019","journal-title":"World J Pediatr Congenit Heart Surg."},{"key":"B29","first-page":"293","article-title":"[Use of ivabradine for the treatment of congenital junctional ectopic tachycardia]","volume":"81","author":"Rios","year":"2021","journal-title":"Medicina."},{"key":"B30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1017\/S1047951120001195","article-title":"Ivabradine as a stabilising anti-arrhythmic agent for multifocal atrial tachycardia","volume":"30","author":"Cohen","year":"2020","journal-title":"Cardiol Young."},{"key":"B31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.hrcr.2019.03.007","article-title":"Ivabradine for treatment of tachyarrhythmias in children and young adults","volume":"5","author":"Janson","year":"2019","journal-title":"HeartRhythm Case Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fped.2020.00313","article-title":"Ectopic atrial tachycardia in a 12-month-old girl treated with ivabradine and beta-blocker, a case report","volume":"8","author":"Michel","year":"2020","journal-title":"Front Pediatr."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur Heart J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur Heart J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijcard.2016.04.136","article-title":"Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study","volume":"217","author":"Hidalgo","year":"2016","journal-title":"Int J Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e004112","DOI":"10.1161\/CIRCHEARTFAILURE.117.004112","article-title":"Ivabradine in heart failure: the representativeness of SHIFT (systolic heart failure treatment with the IF inhibitor ivabradine trial) in a broad population of patients with chronic heart failure","volume":"10","author":"Das","year":"2017","journal-title":"Circ Heart Fail."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s11096-018-0715-8","article-title":"The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis","volume":"40","author":"Hartmann","year":"2018","journal-title":"Int J Clin Pharm."},{"key":"B42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijcard.2017.12.093","article-title":"Optimization of heart rate lowering therapy in hospitalized patients with heart failure: insights from the optimize heart failure care program","volume":"260","author":"Lopatin","year":"2018","journal-title":"Int J Cardiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","article-title":"Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial","volume":"30","author":"Fox","year":"2009","journal-title":"Eur Heart J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"Mcmurray","year":"2012","journal-title":"Eur J Heart Fail."},{"key":"B45","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/VHRM.S90383","article-title":"Advances in the management of heart failure: the role of ivabradine","volume":"12","author":"Muller-Werdan","year":"2016","journal-title":"Vasc Health Risk Manag."},{"key":"B46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1540-8159.2006.00413.x","article-title":"Focal atrial tachycardia I: clinical features, diagnosis, mechanisms, anatomic location","volume":"29","author":"Roberts-Thomson","year":"2006","journal-title":"Pacing Clin Electrophysiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/hrt.2008.143552","article-title":"Focal atrial tachycardia","volume":"96","author":"Rosso","year":"2010","journal-title":"Heart."},{"key":"B48","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1540-8159.2006.00433.x","article-title":"Focal atrial tachycardia II: management","volume":"29","author":"Roberts-Thomson","year":"2006","journal-title":"Pacing Clin Electrophysiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/CIRCEP.113.001423","article-title":"Current management of focal atrial tachycardia in children: a multicenter experience","volume":"7","author":"Kang","year":"2014","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/01.CIR.0000109481.73788.2E","article-title":"Focal atrial tachycardia: new insight from noncontact mapping and catheter ablation","volume":"109","author":"Higa","year":"2004","journal-title":"Circulation."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0735-1097(97)00040-5","article-title":"Evaluation of a staged treatment protocol for rapid automatic junctional tachycardia after operation for congenital heart disease","volume":"29","author":"Walsh","year":"1997","journal-title":"J Am Coll Cardiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1161\/01.CIR.81.5.1544","volume":"81","author":"Villain","year":"1990","journal-title":"Circulation."},{"key":"B53","first-page":"143","article-title":"Congenital junctional ectopic tachycardia: presentation and outcome","volume":"3","author":"Sarubbi","year":"2003","journal-title":"Indian Pacing Electrophysiol J."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.660855\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T04:28:30Z","timestamp":1627964910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.660855\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":53,"alternative-id":["10.3389\/fcvm.2021.660855"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.660855","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]},"article-number":"660855"}}